Geron Corporation
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, …
Biotechnology
US, Foster City [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Geron Corporation's gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2015 | - | 0.004 | - | 36 | - | -13 | - | -13 | - | -14 | - | 15 |
| 2016 | - | -0.185 | - | 6 | - | -105 | - | -6 | - | -6 | - | 656 |
| 2017 | - | -0.170 | - | 1 | - | -97 | - | -1 | - | -1 | - | 121 |
| 2018 | - | -0.157 | - | 0.83 | - | -89 | - | 0.83 | - | 0.83 | - | 87 |
| 2019 | - | -0.420 | - | 0.36 | - | -239 | - | 0.36 | - | 0.36 | - | 38 |
| 2020 | - | -0.262 | - | 0.24 | - | -149 | - | 0.24 | - | 0.24 | - | 25 |
| 2021 | - | -0.336 | - | 0.42 | - | -191 | - | 0.42 | - | 0.42 | - | 44 |
| 2022 | - | -0.383 | - | 0.60 | - | -111 | - | -106 | - | -107 | - | 64 |
| 2023 | - | -0.343 | - | 0.29 | - | -184 | - | -132 | - | -133 | - | 31 |
| 2024 | - | -0.260 | - | 91 | - | -148 | - | -91 | - | -91 | - | 9,736 |
| 2025 | - | -0.072 | - | 301 | - | -46 | - | -301 | - | -301 | - | 32,195 |
| 2026 | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F111/td> | - | 2.F111 | - | 2.F111 |
| 2027 | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F121/td> | - | 1.F121 | - | 1.F121 |
| 2028 | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F131/td> | - | 0.F131 | - | 0.F131 |